KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $777.6 million.

  • Alnylam Pharmaceuticals' Receivables - Net rose 9184.6% to $777.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $777.6 million, marking a year-over-year increase of 9184.6%. This contributed to the annual value of $777.6 million for FY2025, which is 9184.6% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Receivables - Net is $777.6 million, which was up 9184.6% from $964.8 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Receivables - Net registered a high of $964.8 million during Q3 2025, and its lowest value of $110.6 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables - Net was $273.7 million (2022), whereas its average is $326.4 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 294.43% in 2022, then soared by 17264.73% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Receivables - Net (Quarter) stood at $198.6 million in 2021, then rose by 19.84% to $238.0 million in 2022, then surged by 37.75% to $327.8 million in 2023, then rose by 23.65% to $405.3 million in 2024, then skyrocketed by 91.85% to $777.6 million in 2025.
  • Its last three reported values are $777.6 million in Q4 2025, $964.8 million for Q3 2025, and $567.1 million during Q2 2025.